Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies.

Capodivento G, Visigalli D, Garnero M, Fancellu R, Ferrara MD, Basit A, Hamid Z, Pastore VP, Garibaldi S, Armirotti A, Mancardi G, Serrati C, Capello E, Schenone A, Nobbio L.

Sci Rep. 2017 Aug 10;7(1):7831. doi: 10.1038/s41598-017-08314-1.

2.

Serial magnetic resonance study in super refractory status epilepticus: progressive involvement of striatum and pallidus is a possible predictive marker of negative outcome.

Ferrari A, Renzetti P, Serrati C, Fancellu R.

Neurol Sci. 2017 Aug;38(8):1513-1516. doi: 10.1007/s10072-017-3007-5. Epub 2017 Jun 8.

PMID:
28597112
3.

Can long-term thiamine treatment improve the clinical outcomes of myotonic dystrophy type 1?

Costantini A, Trevi E, Pala MI, Fancellu R.

Neural Regen Res. 2016 Sep;11(9):1487-1491.

4.

Long-term treatment with thiamine as possible medical therapy for Friedreich ataxia.

Costantini A, Laureti T, Pala MI, Colangeli M, Cavalieri S, Pozzi E, Brusco A, Salvarani S, Serrati C, Fancellu R.

J Neurol. 2016 Nov;263(11):2170-2178. Epub 2016 Aug 3.

5.

Thiamine and dystonia 16.

Costantini A, Trevi E, Pala MI, Fancellu R.

BMJ Case Rep. 2016 Jul 22;2016. pii: bcr-2016-216721. doi: 10.1136/bcr-2016-216721.

6.

An open-label pilot study with high-dose thiamine in Parkinson's disease.

Costantini A, Fancellu R.

Neural Regen Res. 2016 Mar;11(3):406-7. doi: 10.4103/1673-5374.179047. No abstract available.

7.

Primary AL amyloidosis presenting as lower motor neuron disease.

Fancellu R, Buzzo P, Faga D, Morena M, Racchi O, Salvarani S, Scotto P.

J Neurol Sci. 2016 May 15;364:177-9. doi: 10.1016/j.jns.2016.03.039. Epub 2016 Mar 25. No abstract available.

PMID:
27084240
8.

Challenges in Diagnosis and Treatment of Wernicke Encephalopathy: Report of 2 Cases.

Infante MT, Fancellu R, Murialdo A, Barletta L, Castellan L, Serrati C.

Nutr Clin Pract. 2016 Apr;31(2):186-90. doi: 10.1177/0884533615621753. Epub 2016 Feb 11.

PMID:
26869612
9.

Long-Term Treatment with High-Dose Thiamine in Parkinson Disease: An Open-Label Pilot Study.

Costantini A, Pala MI, Grossi E, Mondonico S, Cardelli LE, Jenner C, Proietti S, Colangeli M, Fancellu R.

J Altern Complement Med. 2015 Dec;21(12):740-7. doi: 10.1089/acm.2014.0353. Epub 2015 Oct 27.

PMID:
26505466
10.

Paraneoplastic cerebellar ataxia associated with anti-Hu antibodies and benign ganglioneuroma.

Fancellu R, Corsini E, Bernardi G, Buzzo P, Ferrari ML, Lamantea E, Garaventa A, Truini M, Salvarani S.

Funct Neurol. 2014 Oct-Dec;29(4):277-80.

11.

Longitudinal study of cognitive and psychiatric functions in spinocerebellar ataxia types 1 and 2.

Fancellu R, Paridi D, Tomasello C, Panzeri M, Castaldo A, Genitrini S, Soliveri P, Girotti F.

J Neurol. 2013 Dec;260(12):3134-43.

PMID:
24122064
12.

Inventory of Non-Ataxia Signs (INAS): validation of a new clinical assessment instrument.

Jacobi H, Rakowicz M, Rola R, Fancellu R, Mariotti C, Charles P, Dürr A, Küper M, Timmann D, Linnemann C, Schöls L, Kaut O, Schaub C, Filla A, Baliko L, Melegh B, Kang JS, Giunti P, van de Warrenburg BP, Fimmers R, Klockgether T.

Cerebellum. 2013 Jun;12(3):418-28. doi: 10.1007/s12311-012-0421-3.

PMID:
23090211
13.

Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial.

Mariotti C, Fancellu R, Caldarazzo S, Nanetti L, Di Bella D, Plumari M, Lauria G, Cappellini MD, Duca L, Solari A, Taroni F.

Mov Disord. 2012 Mar;27(3):446-9. doi: 10.1002/mds.24066. Epub 2012 Jan 4.

PMID:
22411849
14.

The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study.

Jacobi H, Bauer P, Giunti P, Labrum R, Sweeney MG, Charles P, Dürr A, Marelli C, Globas C, Linnemann C, Schöls L, Rakowicz M, Rola R, Zdzienicka E, Schmitz-Hübsch T, Fancellu R, Mariotti C, Tomasello C, Baliko L, Melegh B, Filla A, Rinaldi C, van de Warrenburg BP, Verstappen CC, Szymanski S, Berciano J, Infante J, Timmann D, Boesch S, Hering S, Depondt C, Pandolfo M, Kang JS, Ratzka S, Schulz J, Tezenas du Montcel S, Klockgether T.

Neurology. 2011 Sep 13;77(11):1035-41. doi: 10.1212/WNL.0b013e31822e7ca0. Epub 2011 Aug 10.

15.

Spinocerebellar ataxia types 1, 2, 3 and 6: the clinical spectrum of ataxia and morphometric brainstem and cerebellar findings.

Jacobi H, Hauser TK, Giunti P, Globas C, Bauer P, Schmitz-Hübsch T, Baliko L, Filla A, Mariotti C, Rakowicz M, Charles P, Ribai P, Szymanski S, Infante J, van de Warrenburg BP, Dürr A, Timmann D, Boesch S, Fancellu R, Rola R, Depondt C, Schöls L, Zdzienicka E, Kang JS, Ratzka S, Kremer B, Stephenson DA, Melegh B, Pandolfo M, Tezenas du Montcel S, Borkert J, Schulz JB, Klockgether T.

Cerebellum. 2012 Mar;11(1):155-66. doi: 10.1007/s12311-011-0292-z.

PMID:
21701895
16.

Ataxia with oculomotor apraxia type1 (AOA1): novel and recurrent aprataxin mutations, coenzyme Q10 analyses, and clinical findings in Italian patients.

Castellotti B, Mariotti C, Rimoldi M, Fancellu R, Plumari M, Caimi S, Uziel G, Nardocci N, Moroni I, Zorzi G, Pareyson D, Di Bella D, Di Donato S, Taroni F, Gellera C.

Neurogenetics. 2011 Aug;12(3):193-201. doi: 10.1007/s10048-011-0281-x. Epub 2011 Apr 5.

PMID:
21465257
17.

Depression comorbidity in spinocerebellar ataxia.

Schmitz-Hübsch T, Coudert M, Tezenas du Montcel S, Giunti P, Labrum R, Dürr A, Ribai P, Charles P, Linnemann C, Schöls L, Rakowicz M, Rola R, Zdzienicka E, Fancellu R, Mariotti C, Baliko L, Melegh B, Filla A, Salvatore E, van de Warrenburg BP, Szymanski S, Infante J, Timmann D, Boesch S, Depondt C, Kang JS, Schulz JB, Klopstock T, Lossnitzer N, Löwe B, Frick C, Rottländer D, Schlaepfer TE, Klockgether T.

Mov Disord. 2011 Apr;26(5):870-6. doi: 10.1002/mds.23698. Epub 2011 Mar 21.

PMID:
21437988
18.

Lower limb areflexia without central and peripheral conduction abnormalities is highly suggestive of Gerstmann-Sträussler-Scheinker disease Pro102Leu.

Salsano E, Fancellu R, Di Fede G, Ciano C, Scaioli V, Nanetti L, Politi LS, Tagliavini F, Mariotti C, Pareyson D.

J Neurol Sci. 2011 Mar 15;302(1-2):85-8. doi: 10.1016/j.jns.2010.11.019. Epub 2010 Dec 16.

PMID:
21167505
19.

Predictive genetic tests in neurodegenerative disorders: a methodological approach integrating psychological counseling for at-risk individuals and referring clinicians.

Mariotti C, Ferruta A, Gellera C, Nespolo C, Fancellu R, Genitrini S, Di Bella D, Panzeri M, Nanetti L, Tomasello C, Taroni F, Foresti G, Astori S.

Eur Neurol. 2010;64(1):33-41. doi: 10.1159/000315033. Epub 2010 Jun 30.

PMID:
20588047
20.

Responsiveness of different rating instruments in spinocerebellar ataxia patients.

Schmitz-Hübsch T, Fimmers R, Rakowicz M, Rola R, Zdzienicka E, Fancellu R, Mariotti C, Linnemann C, Schöls L, Timmann D, Filla A, Salvatore E, Infante J, Giunti P, Labrum R, Kremer B, van de Warrenburg BP, Baliko L, Melegh B, Depondt C, Schulz J, du Montcel ST, Klockgether T.

Neurology. 2010 Feb 23;74(8):678-84. doi: 10.1212/WNL.0b013e3181d1a6c9.

PMID:
20177122
21.

Self-rated health status in spinocerebellar ataxia--results from a European multicenter study.

Schmitz-Hübsch T, Coudert M, Giunti P, Globas C, Baliko L, Fancellu R, Mariotti C, Filla A, Rakowicz M, Charles P, Ribai P, Szymanski S, Infante J, van de Warrenburg BP, Dürr A, Timmann D, Boesch S, Rola R, Depondt C, Schöls L, Zdzienicka E, Kang JS, Ratzka S, Kremer B, Schulz JB, Klopstock T, Melegh B, du Montcel ST, Klockgether T.

Mov Disord. 2010 Apr 15;25(5):587-95. doi: 10.1002/mds.22740.

PMID:
20175183
22.

Immunological reactivity against neuronal and non-neuronal antigens in sporadic adult-onset cerebellar ataxia.

Fancellu R, Pareyson D, Corsini E, Salsano E, Laurà M, Bernardi G, Antozzi C, Andreetta F, Colecchia M, Di Donato S, Mariotti C.

Eur Neurol. 2009;62(6):356-61. doi: 10.1159/000242010. Epub 2009 Sep 26.

PMID:
19786780
23.

Rare association of motor neuron disease and spinocerebellar ataxia type 2 (SCA2): a new case and review of the literature.

Nanetti L, Fancellu R, Tomasello C, Gellera C, Pareyson D, Mariotti C.

J Neurol. 2009 Nov;256(11):1926-8. doi: 10.1007/s00415-009-5237-9. Epub 2009 Jul 31. Review.

PMID:
19644730
24.

SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia.

Schmitz-Hübsch T, Giunti P, Stephenson DA, Globas C, Baliko L, Saccà F, Mariotti C, Rakowicz M, Szymanski S, Infante J, van de Warrenburg BP, Timmann D, Fancellu R, Rola R, Depondt C, Schöls L, Zdzienicka E, Kang JS, Döhlinger S, Kremer B, Melegh B, Filla A, Klockgether T.

Neurology. 2008 Aug 12;71(7):486-92. doi: 10.1212/01.wnl.0000324863.76290.19.

PMID:
18695159
25.

Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms.

Schmitz-Hübsch T, Coudert M, Bauer P, Giunti P, Globas C, Baliko L, Filla A, Mariotti C, Rakowicz M, Charles P, Ribai P, Szymanski S, Infante J, van de Warrenburg BP, Dürr A, Timmann D, Boesch S, Fancellu R, Rola R, Depondt C, Schöls L, Zdienicka E, Kang JS, Döhlinger S, Kremer B, Stephenson DA, Melegh B, Pandolfo M, di Donato S, du Montcel ST, Klockgether T.

Neurology. 2008 Sep 23;71(13):982-9. doi: 10.1212/01.wnl.0000325057.33666.72. Epub 2008 Aug 6.

PMID:
18685131
26.

Adult-onset Alexander disease: a series of eleven unrelated cases with review of the literature.

Pareyson D, Fancellu R, Mariotti C, Romano S, Salmaggi A, Carella F, Girotti F, Gattellaro G, Carriero MR, Farina L, Ceccherini I, Savoiardo M.

Brain. 2008 Sep;131(Pt 9):2321-31. doi: 10.1093/brain/awn178. Epub 2008 Aug 6. Review.

PMID:
18684770
27.

Can MR imaging diagnose adult-onset Alexander disease?

Farina L, Pareyson D, Minati L, Ceccherini I, Chiapparini L, Romano S, Gambaro P, Fancellu R, Savoiardo M.

AJNR Am J Neuroradiol. 2008 Jun;29(6):1190-6. doi: 10.3174/ajnr.A1060. Epub 2008 Apr 3.

28.

Diffusion tensor imaging of spinocerebellar ataxias types 1 and 2.

Mandelli ML, De Simone T, Minati L, Bruzzone MG, Mariotti C, Fancellu R, Savoiardo M, Grisoli M.

AJNR Am J Neuroradiol. 2007 Nov-Dec;28(10):1996-2000.

29.

Spinocerebellar ataxia type 17 (SCA17): oculomotor phenotype and clinical characterization of 15 Italian patients.

Mariotti C, Alpini D, Fancellu R, Soliveri P, Grisoli M, Ravaglia S, Lovati C, Fetoni V, Giaccone G, Castucci A, Taroni F, Gellera C, Di Donato S.

J Neurol. 2007 Nov;254(11):1538-46. Epub 2007 Oct 15.

PMID:
17934876
30.

Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease.

Tassorelli C, Armentero MT, Greco R, Fancellu R, Sandrini G, Nappi G, Blandini F.

Brain Res. 2007 Oct 24;1176:53-61. Epub 2007 Aug 14.

PMID:
17884026
31.

Unilateral lesion of the subthalamic nucleus enhances cortical fos expression associated with focally evoked seizures in the rat.

Blandini F, Fancellu R, Armentero MT, Tassorelli C, Greco R, Fornai F, Nappi G.

Brain Res. 2006 Jul 26;1101(1):145-50. Epub 2006 Jun 19.

PMID:
16782074
32.

Scale for the assessment and rating of ataxia: development of a new clinical scale.

Schmitz-Hübsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, Giunti P, Globas C, Infante J, Kang JS, Kremer B, Mariotti C, Melegh B, Pandolfo M, Rakowicz M, Ribai P, Rola R, Schöls L, Szymanski S, van de Warrenburg BP, Dürr A, Klockgether T, Fancellu R.

Neurology. 2006 Jun 13;66(11):1717-20. Erratum in: Neurology. 2006 Jul 25;67(2):299. Fancellu, Roberto [added].

PMID:
16769946
33.

Selective lesion of the substantia nigra pars reticulata reduces the cortical Fos expression induced by stimulation of striatal D1-like receptors, in the rat.

Blandini F, Armentero MT, Tassorelli C, Greco R, Fancellu R, Bramanti P, Nappi G, Martignoni E.

Exp Neurol. 2006 Jul;200(1):240-4. Epub 2006 Mar 6.

PMID:
16516888
34.

Reliability and validity of the International Cooperative Ataxia Rating Scale: a study in 156 spinocerebellar ataxia patients.

Schmitz-Hübsch T, Tezenas du Montcel S, Baliko L, Boesch S, Bonato S, Fancellu R, Giunti P, Globas C, Kang JS, Kremer B, Mariotti C, Melegh B, Rakowicz M, Rola R, Romano S, Schöls L, Szymanski S, van de Warrenburg BP, Zdzienicka E, Dürr A, Klockgether T.

Mov Disord. 2006 May;21(5):699-704.

PMID:
16450347
35.

Peripheral levels of BDNF and NGF in primary headaches.

Blandini F, Rinaldi L, Tassorelli C, Sances G, Motta M, Samuele A, Fancellu R, Nappi G, Leon A.

Cephalalgia. 2006 Feb;26(2):136-42.

PMID:
16426267
36.
37.

Oxidative stress and pro-apoptotic conditions in a rodent model of Wilson's disease.

Samuele A, Mangiagalli A, Armentero MT, Fancellu R, Bazzini E, Vairetti M, Ferrigno A, Richelmi P, Nappi G, Blandini F.

Biochim Biophys Acta. 2005 Sep 25;1741(3):325-30.

38.

An overview of the patient with ataxia.

Mariotti C, Fancellu R, Di Donato S.

J Neurol. 2005 May;252(5):511-8. Review.

PMID:
15895274
39.

Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment.

Blandini F, Cosentino M, Mangiagalli A, Marino F, Samuele A, Rasini E, Fancellu R, Tassorelli C, Pacchetti C, Martignoni E, Riboldazzi G, Calandrella D, Lecchini S, Frigo G, Nappi G.

J Neural Transm (Vienna). 2004 Aug;111(8):1017-30. Epub 2004 Mar 19.

PMID:
15254790
40.

Cognitive and affective status in mild hypothyroidism and interactions with L-thyroxine treatment.

Bono G, Fancellu R, Blandini F, Santoro G, Mauri M.

Acta Neurol Scand. 2004 Jul;110(1):59-66.

PMID:
15180808
41.

Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.

Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G.

Exp Neurol. 2004 Jun;187(2):455-9.

PMID:
15144871
42.

Peripheral markers of apoptosis in Parkinson's disease: the effect of dopaminergic drugs.

Blandini F, Mangiagalli A, Cosentino M, Marino F, Samuele A, Rasini E, Fancellu R, Martignoni E, Riboldazzi G, Calandrella D, Frigo GM, Nappi G.

Ann N Y Acad Sci. 2003 Dec;1010:675-8.

PMID:
15033810
43.

Neuroprotective effects mediated by dopamine receptor agonists against malonate-induced lesion in the rat striatum.

Fancellu R, Armentero MT, Nappi G, Blandini F.

Neurol Sci. 2003 Oct;24(3):180-1.

PMID:
14598076
44.

Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson's disease.

Blandini F, Mangiagalli A, Martignoni E, Samuele A, Fancellu R, Tassorelli C, Cosentino M, Marino F, Rasini E, Calandrella D, Riboldazzi G, Colombo C, Frigo GM, Nappi G.

Neurol Sci. 2003 Oct;24(3):157-8.

PMID:
14598064
45.

Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.

Blandini F, Nappi G, Fancellu R, Mangiagalli A, Samuele A, Riboldazzi G, Calandrella D, Pacchetti C, Bono G, Martignoni E.

J Neural Transm (Vienna). 2003 Aug;110(8):911-22.

PMID:
12898346
46.

Selective stimulation of striatal dopamine receptors of the D1- or D2-class causes opposite changes of fos expression in the rat cerebral cortex.

Blandini F, Fancellu R, Orzi F, Conti G, Greco R, Tassorelli C, Nappi G.

Eur J Neurosci. 2003 Feb;17(4):763-70.

PMID:
12603266
47.

Effects of the intrastriatal administration of selective dopaminergic agonists on Fos expression in the rat brain.

Blandini F, Fancellu R, Orzi F, Conti G, Greco R, Tassorelli C, Nappi G.

Neurol Sci. 2002 Sep;23 Suppl 2:S57-8.

PMID:
12548342
48.

Dopamine receptor agonists mediate neuroprotection in malonate-induced striatal lesion in the rat.

Armentero MT, Fancellu R, Nappi G, Blandini F.

Exp Neurol. 2002 Dec;178(2):301-5.

PMID:
12504889
49.

Neuropsychological changes after carotid endarterectomy.

Sinforiani E, Curci R, Fancellu R, Facchinetti P, Mille T, Bono G.

Funct Neurol. 2001 Oct-Dec;16(4):329-36.

PMID:
11853324
50.

Supplemental Content

Loading ...
Support Center